Pancreatic Cancer Immuno-oncology in the Era of Precision Medicine.

摘要: Pancreatic malignancies carry a dismal prognosis globally, with pancreatic adenocarcinomas (PDAC) being particularly aggressive and stubborn. Unfortunately, several therapeutic strategies that show promise in other cancers have failed to make sizeable impact on tumor outcomes. Responses immunotherapies are especially rare cancer, patients need of innovative approaches can result more durable responses. Current research preclinical models humans has suggested this resistance is due uniquely inflammatory dysfunctional microenvironment; these findings lay the groundwork for targeting barriers improving Clinical analyses also revealed unprecedented heterogeneity stromal biology PDAC, underscoring personalized combinatorial therapies. This review will highlight current state translational focusing PDAC immunity, summarize ongoing clinical efforts tackle vulnerabilities, underscore some unresolved challenges implementing therapies broadly. A better understanding immune contexture disease greatly accelerate drug discovery implementation precision medicine PDAC.